ProMIS Neurosciences Inc. Common Shares (ON) financials
$10.64−0.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$12.3M | -$8.6M | -$10.8M | -$11.8M | -$10.2M | -$7.5M | -$6.0M | -$4.4M | -$2.7M | -$3.7M | -$3.9M | -$2.5M |
| Net income | -$11.7M | -$8.2M | -$10.7M | -$11.6M | -$10.1M | -$7.3M | -$238.2K | $9.3M | -$2.6M | -$3.6M | -$3.6M | -$2.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.28 | $-1.26 | — | $-6.00 | $-7.26 | $-5.27 | $-0.16 | $7.75 | $-3.25 | $-4.75 | $-4.56 | $-4.75 |
| EBITDA | -$12.3M | -$8.6M | -$10.8M | -$11.8M | -$10.2M | -$7.5M | -$6.0M | -$4.4M | -$2.7M | -$3.7M | -$3.9M | -$2.5M |
| Operating cash flow | -$10.4M | -$12.4M | -$9.3M | -$10.1M | -$3.9M | -$4.9M | -$8.7M | -$6.7M | -$1.5M | -$10.3M | -$3.8M | -$2.4M |
| Free cash flow | -$10.4M | -$12.4M | -$9.3M | -$10.1M | -$3.9M | -$4.9M | -$8.7M | -$6.7M | -$1.5M | -$10.3M | -$3.8M | -$2.4M |
| Diluted shares | 9.1M | 6.5M | — | 2.0M | 1.4M | 1.4M | 1.5M | 1.2M | 0.8M | 0.8M | 0.8M | 0.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $53.4M | $63.8M | $6.1M | $15.4M | $4.5M | $8.4M |
| Short-term investments | $33.8K | $33.8K | $33.8K | $33.1K | $33.1K | $33.1K |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $56.7M | $67.4M | $9.2M | $21.5M | $9.5M | $13.6M |
| Total liabilities | $7.3M | $6.7M | $10.4M | $12.3M | $9.9M | $4.2M |
| Shareholders' equity | $49.4M | $60.7M | -$1.3M | $9.2M | -$382.6K | $9.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology